A Mass Balance Study of [14C]HRS-9057 for Injection in Healthy Participants
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Si Chen
- Phone Number: 0518-82342973
- Email: si.chen@hengrui.com
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210036
- First Affiliated Hospital With Nanjing Medical University (Jiangsu Province Hospital )
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Informed consent was obtained voluntarily
- Healthy males aged 18 ~ 45 years (inclusive)
- Body weight ≥50 kg, BMI 19 ~ 28 kg/m2 (inclusive)
- Adopt efficient contraceptive measures
Exclusion Criteria:
- Have a history of drug allergy, specific allergy, or allergic constitution
- Any previous or current medical history that may affect the safety of the participant in the trial or the course of the study drug in vivo
- Have a history of risk factors for torsade de pointes
- During the screening period, serum potassium, sodium, ALT, or AST were beyond the normal range, or the calculated eGFR was less than 90 mL/min/1.73m2
- During screening, 12-lead ECG showed atrioventricular block, atrial fibrillation or flutter, QTcF≥450 ms
- Chest X-ray findings deemed clinically significant by the investigator
- Have positive test results for hepatitis B surface antigen, hepatitis C virus antibody, or treponema pallidum antibody or nonnegative test result for human immunodeficiency virus (HIV) during the screening period
- Have used or are using any prescription or over-the-counter drugs within 2 weeks before the dosing
- Any drug that inhibits or induces hepatic drug-metabolizing enzymes within 4 weeks prior to administration
- All kinds of voiding disorders (such as frequent urination, dysuria, etc.), habitual constipation or diarrhea
- Workers engaged in conditions requiring long-term exposure to radioactivity; Or had significant radiation exposure (≥2 chest/abdominal CT scans, or ≥3 other types of X-ray examinations) within 1 year before the trial or had participated in a radiolabeled drug trial within 1 year
- Participants may have been unable to complete the study for other reasons or may have been deemed by the investigator to be unsuitable for enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dose Level:A
Subject will receive [14C]HRS-9057 at dose level A
|
[14C]HRS-9057
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Total radioactivity recovery and cumulative total radioactivity recovery in urine and feces during each collection period
Time Frame: From Day 1 to Day 28
|
From Day 1 to Day 28
|
|
Percentage of HRS-9057 parent drug and its metabolites in plasma relative to the total radioactivity exposure in plasma (%AUC)
Time Frame: From Day 1 to Day 8
|
From Day 1 to Day 8
|
|
The percentage of HRS-9057 parent drug and its metabolites in urine and feces relative to the administered dose (%Dose)
Time Frame: From Day 1 to Day 28
|
From Day 1 to Day 28
|
|
Pharmacokinetic parameter of total radioactivity in whole blood and plasma, including: Tmax
Time Frame: From Day 1 to Day 28
|
From Day 1 to Day 28
|
|
Pharmacokinetic parameter of total radioactivity in whole blood and plasma, including: Cmax
Time Frame: From Day 1 to Day 28
|
From Day 1 to Day 28
|
|
Pharmacokinetic parameter of total radioactivity in whole blood and plasma, including: t1/2
Time Frame: From Day 1 to Day 28
|
From Day 1 to Day 28
|
|
Pharmacokinetic parameter of total radioactivity in whole blood and plasma, including: MRT
Time Frame: From Day 1 to Day 28
|
From Day 1 to Day 28
|
|
Pharmacokinetic parameter of total radioactivity in whole blood and plasma, including: AUC
Time Frame: From Day 1 to Day 28
|
From Day 1 to Day 28
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Pharmacokinetic parameter of HRS-9057, and other major metabolites (if applicable) in plasma, including: Tmax
Time Frame: From Day 1 to Day 28
|
From Day 1 to Day 28
|
|
Pharmacokinetic parameter of HRS-9057, and other major metabolites (if applicable) in plasma, including: Cmax
Time Frame: From Day 1 to Day 28
|
From Day 1 to Day 28
|
|
Pharmacokinetic parameter of HRS-9057, and other major metabolites (if applicable) in plasma, including: t1/2
Time Frame: From Day 1 to Day 28
|
From Day 1 to Day 28
|
|
Pharmacokinetic parameter of HRS-9057, and other major metabolites (if applicable) in plasma, including: MRT
Time Frame: From Day 1 to Day 28
|
From Day 1 to Day 28
|
|
Pharmacokinetic parameter of HRS-9057, and other major metabolites (if applicable) in plasma, including: AUC
Time Frame: From Day 1 to Day 28
|
From Day 1 to Day 28
|
|
Serious adverse events
Time Frame: From ICF signing date to Day 28
|
From ICF signing date to Day 28
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- HRS-9057-105
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.